Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
Recruiting
N/A
Interventional Study
Pheochromocytoma/Paraganglioma (PPGL)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 40 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-LM3 PET/CT and compare it with 68Ga-DOTATATE PET/CT in patients with pheochromocytoma/paraganglioma (PPGL).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged 18 to 80 years.
* Suspected or confirmed PPGL patients.
Exclusion Criteria:
* Combined with other types of tumors.
* Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min).
* Pregnant or breast-feeding women.
* Inability to perform PET/CT scans.
Contacts